- Home
- ANNX vs PCAP Comparison
ANNX vs PCAP Comparison
Compare ANNX & PCAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- PCAP
- Stock Information
- Founded
- ANNX 2011
- PCAP 2025
- Country
- ANNX United States
- PCAP United States
- Employees
- ANNX N/A
- PCAP N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- PCAP
- Sector
- ANNX Health Care
- PCAP
- Exchange
- ANNX Nasdaq
- PCAP Nasdaq
- Market Cap
- ANNX 334.1M
- PCAP 324.1M
- IPO Year
- ANNX 2020
- PCAP 2025
- Fundamental
- Price
- ANNX $3.20
- PCAP $10.41
- Analyst Decision
- ANNX Strong Buy
- PCAP
- Analyst Count
- ANNX 4
- PCAP 0
- Target Price
- ANNX $13.00
- PCAP N/A
- AVG Volume (30 Days)
- ANNX 2.0M
- PCAP 86.6K
- Earning Date
- ANNX 11-13-2025
- PCAP 01-01-0001
- Dividend Yield
- ANNX N/A
- PCAP N/A
- EPS Growth
- ANNX N/A
- PCAP N/A
- EPS
- ANNX N/A
- PCAP N/A
- Revenue
- ANNX N/A
- PCAP N/A
- Revenue This Year
- ANNX N/A
- PCAP N/A
- Revenue Next Year
- ANNX N/A
- PCAP N/A
- P/E Ratio
- ANNX N/A
- PCAP N/A
- Revenue Growth
- ANNX N/A
- PCAP N/A
- 52 Week Low
- ANNX $1.29
- PCAP $9.64
- 52 Week High
- ANNX $7.64
- PCAP $11.42
- Technical
- Relative Strength Index (RSI)
- ANNX 58.77
- PCAP N/A
- Support Level
- ANNX $2.89
- PCAP N/A
- Resistance Level
- ANNX $3.36
- PCAP N/A
- Average True Range (ATR)
- ANNX 0.21
- PCAP 0.00
- MACD
- ANNX -0.03
- PCAP 0.00
- Stochastic Oscillator
- ANNX 67.35
- PCAP 0.00
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About PCAP ProCap Acquisition Corp Class A Ordinary Shares
ProCap Acquisition Corp is a blank check company.